Discrepancies in Hospital Cost and Indonesia's Case-based Groups: A Literature Review

https://doi.org/10.22146/jmpf.95970

Oskar Skarayadi(1), Dwi Endarti(2*), Satibi Satibi(3), Ali Ghufron Mukti(4)

(1) *) Doctor in Pharmaceutical Sciences Program, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta *) Faculty of Pharmacy, Universitas Jenderal Achmad Yani, Cimahi
(2) Department of Pharmaceutics, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta
(3) Department of Pharmaceutics, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta
(4) Department of Health Policy and Management, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta
(*) Corresponding Author

Abstract


Background: Indonesia started establishing national health insurance in 2014. Implementation of Indonesian national health insurance has frequent gaps between health expenditures based on hospital tariffs and the INA-CBG tariff

Objectives: This review was aimed to compare the hospital tariff of healthcare to the INA-CBGs tariff and to identify the factors contributing to the actual cost.

Methods: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology followed in this research. The keywords "Real Cost and INA CBG'S" were used in Google Scholar, and the keywords "INA CBG'S AND REAL COST" on Pubmed, ScienceDirect, and Scopus between 2014 and 2022.

Results: A total of 634 records were found through database searching of Google Scholar (594), Pubmed (1), ScienceDirect (36), and Scopus (3). After the screening process, 24 articles were included in the review. It was found that 13 articles (54.16%) showed a lower hospital tariff than INA CBG's tariff, while 11 articles (45.84%) showed a higher hospital tariff than INA CBG's tariff. The main factors affecting the gaps of hospital tariff versus INA CBGs tariff mentioned in the articles were LOS, severity, and hospitality class.

Conclusion: The literature of this review found hospital rates are higher with rates of INA-CBGs in many hospitals, so it requires a review of rates and an efficient strategy of hospitals.


Keywords


Cost Containment; Discrepancies; Hospital Tariff; INA-CBG’S

Full Text:

PDF


References

  1. Kemenkes. Regulation of The minister of health of Indonesia number 27 of 2014 technical instructions for the INA-CBG system. Published online 2014.
  2. Zafirah SA, Nur AM, Ezat S, Puteh W, Aljunid SM. Potential loss of revenue due to errors in clinical coding during the implementation of the Malaysia diagnosis related group ( MY-DRG ® ) Casemix system in a teaching hospital in Malaysia. Published online 2018:1-11. doi:10.1186/s12913-018-2843-1
  3. Vozikis A, Xesfingi S, Moustaferi E, Balbouzis T, Rigatos T. The DRG-based hospital prospective payment system in Greece: an assessment of the reimbursement rates using clinical severity classification. Mod Econ. 2016;07(13):1584-1600. doi:10.4236/me.2016.713141
  4. Hadning I, Fathurrohmah F. Stroke Treatment Cost Analysis for Consideration on Health Cost Determination Using INA-CBG’S (Indonesia Case Based Groups) in Indonesia National Health Insurance Programme 2014. Value Heal. 2016;19(7):A866. doi:10.1016/j.jval.2016.08.390
  5. Mboi N. Indonesia: on the way to universal health care. Heal Syst Reform. 2015;1(2)::91-97. doi:10.1080/23288604.2015.1020642
  6. Ambarriani AS. Hospital financial performance in the Indonesian national health insurance era. Rev Integr Bus Econ Res. 2014;4(1):121-133.
  7. Putra RSP, Indar, Jafar N. Ability to pay and catastrophic payment for self paying participants BPJS kesehatan Makassar City. JST Kesehat. 2014;4(3):283-290.
  8. Sinaga ES, Ginting IR, Kusumaratna RK, Marthias T. Evaluation of national health insurance program implementation in Jakarta Province, Indonesia. J Kebijak Kesehat Indones JKKI. 2021;10(03):1-9.
  9. Handayani L, Suharmiati, Pratiwi NL. Hospital unit cost and INA-CBGs tariff : is the hospital health services paid fair? Bul Penelit Sist Kesehat. 2019;21(4):219-227.
  10. Dwidayati A, Andayani TM, Wiedyaningsih C. Comformity analysis of real cost to INA-CBG’S Tariff in non hemorrhagic stroke treatment Of hospitalized JKN patients at Dr. Soehadi Prijonegoro Hospital Sragen 2015. J Farm Indones. 2016;13(2):139-149. http://farmasiindonesia.setiabudi.ac.id/
  11. Meng Z, Hui W, Cai Y, Liu J, Wu H. The effects of DRGs-based payment compared with cost-based payment on inpatient healthcare utilization: A systematic review and meta-analysis. Health Policy (New York). 2020;124(4):359-367. doi:10.1016/j.healthpol.2020.01.007
  12. Meng Z, Hui W, Cai Y, Liu J, Wu H. The effects of DRGs-based payment compared with cost-based payment on inpatient healthcare utilization : A systematic review and. Health Policy (New York). 2020;124(4):359-367. doi:10.1016/j.healthpol.2020.01.007
  13. Agustina, Palu B, Muchlis N. Analysis of real costs and INA-CBG’s tariff at The Bahagia General Hospital in Makassar City. J Muslim Community Heal. 2020;1(2):13-25.
  14. Astuti ND, Irmawati I, Apifah A. Analysis of hospital inpatient costs and INA-CBGs tariffs for congestive heart failure. J Rekam Medis dan Inf Kesehat. 2021;4(1):44-51. doi:10.31983/jrmik.v4i1.6788
  15. Aisyah N, Aryzki S, Wahyuni A, Andayani TM, Puspandari DA. Factors affecting the real cost Of chemotherapy for patients with breast cancer of JKN participants in RSUD Ulin Banjarmasin. J Curr Pharm Sci. 2019;2(2):2598-2095.
  16. Cahyani DP, Yuswar MA, Nurmainah. Analysis the conformity of real costs against INA-CBGs tariffs in ischemic stroke treatment of JKN patients inpatient at Sultan Syarif Mohamad Alkadrie Hospital Pontianak in 2018. J Mhs Farm Fak Kedokt UNTAN. 2019;4(1).
  17. Chetrine. H, Nugraheni. DA, Rugiarti. ND, Tetuko. A. Comparison of Indonesian-Case Based Groups tariffs on inpatient ischemic stroke in government hospital. 2022;5(1):1-6.
  18. Damara AY. The difference between hospital rates and Ina-CBG’S rates at Ryacudu Hospital Kotabumi in 2020. E-Indonesian J Heal Med. 2022;2(3):322-332. http://ijohm.rcipublisher.org/index.php/ijohm
  19. Dewi BA, Andayani TM. Cost Compliance nnalysis of real therapy and INA- CBG ’ s of chemotherapy breast cancer inpatien At 2017 Dr . Moewardi Surakarta Hospital. Str J Ilm Kesehat. 2021;10(1):1234-1241. doi:10.30994/sjik.v10i1.543
  20. Hayul H, Andayani TM, Oetari. Analysis of conformity real costs for determining INA-CBG’S tariffs for inpatient diabetic nephropathy at Ir.Soekarno Sukoharjo Hospital in 2018. J Farm Sains Indones. 2020;3(1):26-36.
  21. Lakoan MR, Andayani TM, Chairun W. Analysis of Conformity of Real Costs Against Ina-CBG’s Tariff in the Treatment of Congestive Heart Failure for Inpatients at Hospital Dr. Soehadi Prijonegoro Sragen 2015. J Farm Sains Indones. 2019;2(2):1-8.
  22. Oktadiana I. Comformity of Real Cost to INA-CBG’s Cost in Hypertension Treatment at Pandan Arang Hospital Boyolali 2017. J Farm Indones. 2019;16(2):106-117. jfi.setiabudi.ac.id
  23. Manawan F, Widodo G, Andayani TM. Cost of illness in breast cancer patients at The National General Hospital Prof. Dr. R.D Kandou Manado. J Farm Medica/Pharmacy Med J. 2019;2(2):86. doi:10.35799/pmj.2.2.2019.26532
  24. Negara SBSMK, Octavia DR, Utami PR. The comparison of the actual cost to csse-mix of Type 2 diabetes mellitus inpatient in Pandan Arang Boyolali Hospital. Pharm Educ. 2021;21(2):269-274. doi:10.46542/pe.2021.212.269274
  25. Nisa BI, Raharjo BB. Determinants of difference in real costs and INA-CBG’s fariff in coronary heart patients. Higeia J Public Heal Res Dev. 2021;1(3):84-94. https://journal.unnes.ac.id/sju/index.php/higeia/article/view/37998
  26. Rahmani N, Sarnianto P, Ramadaniati HU. Analysis of treatment profile, hospital cost perspective and HROQoL in outpatient hemodialysis patients at Fatmawati General Hospital, Jakarta. Nusant J Ilmu Pengetah Sos. 2022;7(2):408-420.
  27. Santoso A, Sulistyaningrum IH, Rosyid A, et al. Comparative of real cost against the price of INA CBG breast cancer and its affecting factors in JKN Program era. Farm Sains dan Prakt. 2020;6(1):60-66.
  28. Satibi S, Andayani TM, Endarti D, Suwantara IPT, Wintariani NP, Agustini NPD. Comparison of real cost versus The Indonesian Case Base Groups (INA-CBGs) tariff rates among patients of high- incidence cancers under the national health insurance scheme. Asian Pacific J Cancer Prev. 2019;20(1):117-122. doi:10.31557/APJCP.2019.20.1.117
  29. Siwi MAA, Andayani TM, Herowati R. Factors affecting the cost of therapy for radius ulna fracture patients by orif surgery And the suitability with INA-CBG’S tariff in RSUD Sukoharjo Regency. 2016;13(2):117-125.
  30. Sofan A, Syamsudin. Analysis of treatment costs for inpatient ischemic stroke patients at RSUD Dr.Drajat Prawira Negara Serang. J Ilm Indones. 2021;6(3).
  31. Sulistyaningrum IH, Santoso A, Binarti. Analysis of Differences in real costs with INA-CBG’s tariffs and factors affecting for chronic kidney disease in the era of National Health Insurance. Indones J Med Pharm Sci. 2021;1(1):6-12. doi:10.30659/ijmps.v1i1.2
  32. Tusshaleha LA. Analysis of real cost Conformity of rectal cancer chemotherapy patients with INA-CBGs Tariff for the implementation of National Health Insurance at Sanglah General Hospital Denpasar in 2014. J Ilm Mandala Educ. 2018;4(1):156. doi:10.36312/jime.v4i1.337
  33. Kusuma AAMW, Ariawati K. The Discrepancy between hospital and INA-CBG’s tariff of thalassemia disease at pediatric ward Sanglah Bali Hospital in 2017. J Penelit dan Pengemb Pelayanan Kesehat. 2018;2(2):95-101.
  34. Wirastuti K, Sulistyaningrum IH, Cahyono EB, et al. Comparison of real costs with INA-CBG’S tariff of stroke in the era of national health insurance at Sultan Agung Islamic Hospital. J Ilm Ibnu Sina Ilmu Farm dan Kesehat. 2019;4(1):117-126. doi:10.36387/jiis.v4i1.244
  35. Wirantari NP, Gunawijaya E, Yantie NPVK. Cost analysis of congenital heart diseasepatients who underwent diagnostic catheterization. Paediatr Indones Indones. 2020;60(5):244-252. doi:10.14238/pi60.5.2020.244-52
  36. Thabrany H. Comparison of catastrophic disease claims for National Health Insurance participants in DKI Jakarta and East Nusa Tenggara Provinces in 2014. Pelatih RSPAD. Published online 1998:2-6.
  37. Panella M, Marchisio S, Di Stanislao F. Reducing clinical variations with clinical pathways: Do pathways work? Int J Qual Heal Care. 2003;15(6):509-521. doi:10.1093/intqhc/mzg057
  38. Tynkkynen LK, Vrangbæk K. Comparing public and private providers: A scoping review of hospital services in Europe. BMC Health Serv Res. 2018;18(1):1-14. doi:10.1186/s12913-018-2953-9
  39. Tiemann O, Schreyögg J, Busse R. Hospital ownership and efficiency: A review of studies with particular focus on Germany. Health Policy (New York). 2012;104(2):163-171. doi:10.1016/j.healthpol.2011.11.010
  40. Bonastre J, Chevalier J, Van der Laan C, Delibes M, De Pouvourville G. Access to innovation: Is there a difference in the use of expensive anticancer drugs between French hospitals? Health Policy (New York). 2014;116(2-3):162-169. doi:10.1016/j.healthpol.2013.11.006
  41. Heniwati, Thabrany H. Comparison of catastrophic disease claims for National Health Insurance participants in DKI Jakarta and East Nusa Tenggara Provinces in 2014. J Ekon Kesehat Indones. 2017;1(2):18-27. doi:10.7454/eki.v1i2.1771
  42. Cook K, Dranove D, Sfekas A. Does major illness cause financial catastrophe? Health Serv Res. 2010;45(2):418-436. doi:10.1111/j.1475-6773.2009.01049.x
  43. Aulia S, Supriadi, Sari D, Mutiha A. Cost recovery rate of the BPJS National Health Insurance Program. Akuntabilitas. 2015;8(2):111-120.
  44. Salim MF, Lubis IK, Sugeng S. Differences in length of stay (LOS) in diabetes mellitus patients based on complications at Dr. Sardjito Yogyakarta. J Manaj Inf Kesehat Indones. 2019;7(1):17. doi:10.33560/jmiki.v7i1.216
  45. Taheri PA, Butz DA, Greenfield LJ. Length of stay has minimal impact on the cost of hospital admission. J Am Coll Surg. 2000;191(2):123-130. doi:10.1016/S1072-7515(00)00352-5
  46. Puspandari DA, Mukti AG, Kusnanto H, Kebijakan P, Asuransi M. Determinant factors of drug cost for breast cancer patient in Indonesia. J Kebijak Kesehat Indones JKKI. 2015;04(03):104-108.
  47. Agboado G, Peters J, Donkin L. Factors influencing the length of hospital stay among patients resident in Blackpool admitted with COPD: A cross-sectional study. BMJ Open. 2012;2(5). doi:10.1136/bmjopen-2012-000869
  48. Puspitorini S, Kusumadewi S, Rosita L. Prediction of disease case severity level to determine INA- CBGs rate. In: IOP Conference Series: Materials Science and Engineering. Vol 185. ; 2017. doi:10.1088/1742-6596/755/1/011001
  49. Kula JI. Hospitalization fee determination method on BLU RSUP Prof. Dr. R. D. Kandou Manado. J EMBA. 2013;Vol 1 No 3(3):793-803.
  50. Muslimah., Tri M.A., Rizaldy, P., Dwi E. Comparison of real costs againts the price of INA-CBG’s Ischemic store in Bethesda hospital Yogyakarta. J Manaj dan Pelayanan Farm. 2017;7(2):105-114.
  51. Satibi S, Daulay EH, Oviani GA, Erlianti K, Fudholi A, Puspandari DA. Performance analysis of pharmacist and influencing factors in the era of National Health Insurance at Puskesmas. J Manag Pharm Pract. 2018;8(1):32. doi:10.22146/jmpf.34441
  52. Trimarchi L, Caruso R, Magon G, Odone A, Arrigoni C. Clinical pathways and patient-related outcomes in hospital-based settings: A systematic review and meta-analysis of randomized controlled trials. Acta Biomed. 2021;92(1):1-13. doi:10.23750/abm.v92i1.10639
  53. Rotter T, Kinsman L, James E, et al. Clinical pathways: effects on professional practice, patient outcomes, length of stay and hospital costs. Cochrane database Syst Rev. 2010;(3):CD006632. doi:10.1002/14651858.CD006632.pub2
  54. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258-2266. doi:10.1002/cncr.21847
  55. Wineinger NE, Zhang Y, Topol EJ. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States. 2019;2(5):1-9. doi:10.1001/jamanetworkopen.2019.4791
  56. Suda KJ, Kim KC, Hernandez I, et al. The global impact of COVID-19 on drug purchases: A cross-sectional time series analysis. J Am Pharm Assoc. 2022;62(January):766-774.
  57. Pontes MA, Robeiro AA, Raijche M, Rover M, Leite SN. Rising drug prices in Brazil during COVID-19 pandemic : another threat to people ’ s health. Brazilian J Pharm Sci. 2022;58(3):1-4. doi:https://doi.org/10.1590/s2175-97902022e20863
  58. Bosworth A, Sheingold S, Finegold K, Sayed BA, Lew N De, Sommers BD. Changes in the List Prices of Prescription Drugs ,. 2023;(October):2017-2023.



DOI: https://doi.org/10.22146/jmpf.95970

Article Metrics

Abstract views : 17 | views : 2

Refbacks

  • There are currently no refbacks.


Copyright (c) 2025 JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

©Jurnal Manajemen dan Pelayanan Farmasi
Faculty of Pharmacy
Universitas Gadjah Mada
Creative Commons License
View My Stats